# Alzamend Neuro, Inc. (ALZN)

> Source: Nexqual · https://nexqual.com/ALZN · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, Alzamend Neuro, Inc. (ALZN), nexqual.com/ALZN" · informational, not investment advice.

**Price:** USD 1.28 (-5.18% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 1.28 · day 1.28–1.33 · 52w 0.84–2.68 · market cap null · NCM

## Key facts
- Analysts: Buy (mean 2.00 on a 1–5 scale) (1 analysts), mean target USD 26 (range 26–26).
- Total return with dividends: 1Y -45.8% vs S&P 500 +18.1%; 5Y -100.0% vs S&P 500 +85.1%.

## Analysts
Consensus Buy (mean 2.00 on a 1–5 scale), 1 analysts; mean target USD 26 (low 26, high 26).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-19 | Ascendiant Capital | Target raised | Buy | $25 → $26 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2021-10-11) |
|---|---|---|
| Total return | -45.8% | -100.0% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -45.9% | -79.0% |
| Volatility (annualized) | 83.3% | 90.8% |
| Max drawdown | -67.1% (Oct 2025→Apr 2026) | -100.0% (Nov 2021→Apr 2026) |

## Peers (Biotechnology)
RYTM (Rhythm Pharmaceuticals, Inc.) USD 87.97 +1.57% · BLTE (Belite Bio, Inc) USD 152.62 +0.49% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.72 +1.52% · PRAX (Praxis Precision Medicines, Inc) USD 248.24 +2.01% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.12 +4.11% · SYRE (Spyre Therapeutics, Inc.) USD 80.1 -0.44%

## More
Full page: https://nexqual.com/ALZN · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt